APA (7th ed.) Citation

Shen, R., Cao, W., Wang, L., Sheng, L., Zhang, Y., Wu, W., . . . Zhao, W. (2025). Response‐adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T‐cell therapy in relapsed/refractory large B‐cell lymphoma: A retrospective observational study. Clinical & Translational Medicine, 15(4), 1. https://doi.org/10.1002/ctm2.70310

Chicago Style (17th ed.) Citation

Shen, Rong, et al. "Response‐adapted Zanubrutinib and Tislelizumab as a Potential Strategy to Enhance CD19 CAR T‐cell Therapy in Relapsed/refractory Large B‐cell Lymphoma: A Retrospective Observational Study." Clinical & Translational Medicine 15, no. 4 (2025): 1. https://doi.org/10.1002/ctm2.70310.

MLA (9th ed.) Citation

Shen, Rong, et al. "Response‐adapted Zanubrutinib and Tislelizumab as a Potential Strategy to Enhance CD19 CAR T‐cell Therapy in Relapsed/refractory Large B‐cell Lymphoma: A Retrospective Observational Study." Clinical & Translational Medicine, vol. 15, no. 4, 2025, p. 1, https://doi.org/10.1002/ctm2.70310.